Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is thought to exert its effects by enhancing the activity of the inhibitory neurotransmitter GABA.
## Primary Indications
Adjunctive treatment for Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase by 5 mg to 10 mg every week to a target dose of 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2 years and older)
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase by 5 mg to 10 mg every week to a target dose of 10 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day). Dosing should be individualized.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; consider lower doses.
* **Concomitant CYP2C19 Inhibitors:** May require dose reduction of clobazam.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, aggression, irritability, constipation, decreased appetite, ataxia, pyrexia, pneumonia.
* **Serious:** Serious skin reactions (e.g., Stevens-Johnson syndrome), respiratory depression, suicidal behavior and ideation, withdrawal symptoms upon discontinuation.
## Key Drug Interactions
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam levels and risk of adverse effects.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam levels.
* **CNS Depressants (e.g., opioids, alcohol):** Additive sedative effects and increased risk of respiratory depression.
* **Other Anticonvulsants:** Potential for additive CNS depression or altered efficacy.
## Monitoring
* Monitor for somnolence, behavioral changes, and signs of respiratory depression.
* Assess for efficacy and tolerability.
* Monitor for signs of withdrawal symptoms if discontinuing.
* Consider monitoring for serious skin reactions.
## Clinical Pearls
* Clobazam is associated with a risk of serious skin reactions; patients should be advised to seek immediate medical attention if a rash develops.
* Due to the risk of somnolence, patients should be cautioned about driving or operating heavy machinery until they know how clobazam affects them.
* Abrupt discontinuation can lead to withdrawal symptoms; gradual tapering is recommended.
* Clobazam is a Schedule IV controlled substance.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any clinical decisions. Dosing and management may vary based on individual patient factors and local protocols.
